NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
nasdaq inducement grant exceptionregulatory
A Nasdaq inducement grant exception is a narrow rule that lets a listed company give stock or options to a newly hired employee without first getting shareholder approval, provided the award meets strict size, timing and disclosure conditions. For investors it matters because such grants can dilute existing shares, signal how the company attracts talent, and affect executive incentives—similar to a signing bonus paid partly in stock instead of cash.
restricted stock unitsfinancial
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionsfinancial
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BOSTON--(BUSINESS WIRE)--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee.The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on July 1, 2026. A total of 393,750 restricted stock units granted to the 29 new employees and the stock options to purchase 91,000 shares of common stock granted to one new employee will vest at a rate of 25% on the one-year anniversary of each employee’s date of hire, with the remaining shares vesting quarterly over the next three years in equal quarterly amounts, provided the employee is employed by or providing other services for Verastem Oncology on each such vesting date. In addition, 6,000 restricted stock units granted to one new employee will vest upon the one-year anniversary of the employee's date of hire, provided the employee is employed by or providing other services for Verastem Oncology on such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications, Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com
